Startups
One entity will focus on pharmaceuticals and drug development, while the other will be aimed at consumer healthcare.
It plans to launch a new, independent, publicly-traded company to handle those products. No name for the new company has been announced.
“Anteros Pharmaceuticals is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the Strategic Partnership Agreement,” said Satish Jindal, BioMotiv’s chief executive officer.
The new entity, funded by $55 million from the BCBS businesses, was born as a response to the high costs of prescription medicines in the United States and concerns about the overall affordability of health care.
With a massive $200 million Series A financing round, EQRx launches with the mission of creating novel medicines that are more affordable for patients and more sustainable for healthcare systems.
Roivant Sciences, helmed by biotech billionaire Vivek Ramaswamy, launched a new subsidiary, Lokavant, a technology company with the important mission of ensuring that no clinical trial fails due to operational error.
Tyra Biosciences, based in Carlsbad, California, closed on a Series A financing worth $50 million.
While Allergan and AbbVie prepare to complete their $63 billion merger later this year, plans are being laid out for a new, stand-alone company called Allergan Aesthetics that will include Botox as a tent pole.
Auris Medical Holding Ltd. announced the formation of a new subsidiary, Zilentin Ltd., to bundle its development projects for the treatment of tinnitus and hearing loss in a separate entity.
Sumitovant will run as a wholly owned subsidiary of Sumitomo Dainippon Pharma.
PRESS RELEASES
